The dream of a vaccine that can treat cancer is moving closer to reality, powered by the same mRNA technology used for COVID-19. A Hyderabad-based startup, PopVax, is one of the players aiming to make this a reality for India.
The Promise of a Personalised Shot
For decades, the primary
weapons against cancer have been surgery, radiation, and chemotherapy—blunt instruments that often cause significant collateral damage to the body. The new frontier is immunotherapy, which trains the body's own immune system to fight cancer. Within this field, personalised cancer vaccines are creating significant excitement. Unlike preventative vaccines, these are therapeutic, designed to treat existing disease. The core idea is that every person's tumour is unique, with its own specific genetic mutations. A personalised vaccine analyses a patient's tumour, identifies these unique markers (called neoantigens), and then uses that information to create a custom vaccine. This vaccine teaches the patient's immune cells to recognise and attack only the cancer cells, leaving healthy tissue unharmed.
PopVax's High-Tech Blueprint
Hyderabad-based PopVax, founded in 2021, is at the forefront of this effort in India. The company uses a combination of artificial intelligence (AI) and machine learning to accelerate the process of identifying the best neoantigens from a patient's tumour sequence. Once these targets are identified, the company uses mRNA technology to build the vaccine. This is the same basic technology that allowed for the rapid development of COVID-19 vaccines. The mRNA carries instructions that, once inside the body, tell cells to produce proteins that mimic the tumour's neoantigens. This provides a training ground for the immune system. PopVax's mission is to develop precision immunotherapies for hard-to-treat solid tumours like liver and pancreatic cancer. The company operates out of its 'RNA Foundry' in Hyderabad, an integrated facility for research, development, and manufacturing.
The 'Unproven' Hurdle: Clinical Trials
While the science is promising, the headline's crucial caveat is that clinical effectiveness remains unproven. This is the reality for all early-stage medical research. Promising lab results do not always translate to effective human treatments. Any new therapy must pass through rigorous, multi-phase clinical trials to prove it is both safe and effective. PopVax, a clinical-stage company, began its first human trial for a COVID-19 vaccine in Australia in August 2026. Its personalised cancer immunotherapy programs for liver and pancreatic cancer are projected to enter Phase I trials in 2027. These early trials focus primarily on safety and determining the right dosage. It will take several more years and larger trials to determine if the vaccines can meaningfully extend patients' lives.
Global Progress and the Road Ahead
PopVax is not alone in this race. Globally, major pharmaceutical companies like Moderna and Merck have seen encouraging results. Their personalised mRNA vaccine, when combined with the immunotherapy drug Keytruda, was recently shown in a large Phase 3 trial to reduce the risk of recurrence or death in high-risk melanoma patients by 42%. This is considered a major milestone and the strongest evidence yet for this approach. However, success in one cancer type doesn't guarantee success in others. A different mRNA vaccine from another company recently failed to meet its goals in a trial for head and neck cancer, highlighting the challenges. The path forward for PopVax involves navigating the lengthy and expensive clinical trial process. The company notes that for severe cancers with few treatment options, it may be possible to get accelerated approvals, but for vaccines given to healthier individuals, the process is much longer. The ultimate goal, for PopVax and the entire field, is to make cancer a manageable chronic condition rather than a death sentence.
